Navigation Links
Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
Date:9/23/2008

SOUTH SAN FRANCISCO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that it has initiated a study, in collaboration with the Dana-Farber Cancer Institute (DFCI), to evaluate Monogram's HERmark(TM) Breast Cancer Assay in metastatic breast cancer.

In the study, Monogram's proprietary HERmark assay will be used to analyze approximately 600 tissue samples from patients with breast cancer, approximately half of whom were eligible for treatment with Herceptin(R) on the basis of prior HER2 IHC and/or FISH testing. HERmark measurements of HER2 total protein and HER2 homodimer levels will be compared with the results of IHC and/or FISH testing as well as response to treatment with Herceptin.

"Results from prior studies in metastatic breast cancer have suggested that HERmark can identify subsets of patients with different responses to Herceptin even though they had all been previously assessed as 'HER2-positive' by IHC and/or FISH, tested centrally," said Michael Bates, M.D., Monogram's Vice President of Clinical Research. "The aim of this study is to test the hypothesis that HERmark selects patients for Herceptin treatment in the metastatic setting better than other currently available assays, as well as to test cutoff values that have been previously defined for HERmark. In addition, we will also measure HER3 expression levels in these tumors and see if they correlate with clinical outcomes in this cohort. The study will also provide enough tissue to facilitate testing of assays that are in advanced development at Monogram, including assays for HER1 expression, p95 expression, as well as heterodimers of HER2, such as HER2:HER3 and HER1:HER2."

"The VeraTag technology repres
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
3. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
4. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
5. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
6. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
7. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... N.Y., Aug. 1, 2011 Nycomed US Inc. ("Nycomed US") ... and Chief Executive Officer and member of the Board for ... the closing of the acquisition of Nycomed A/S by Takeda ... Bailey to the newly created position of Chief Operating Officer, ...
... a biopharmaceutical company pioneering a novel class of ... an entirely new class of naturally occurring human ... of these naturally supercharged human proteins enable biologic ... cells. This new class of proteins is the ...
... in the body, then alarm bells start ringing. ... disease and type 2 diabetes, formerly called adult-onset diabetes. ... then they might be able to treat such diseases ... colleagues at the Helmholtz-Zentrum Dresden-Rossendorf and the university in ...
Cached Biology Technology:Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 2Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 3Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 2Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 3In the pursuit of dangerous clumps 2In the pursuit of dangerous clumps 3
(Date:7/9/2014)... Tampa, Fla. (July 9, 2014) Emerging fungal ... any other parasitic group, causing population declines of ... from the University of South Florida published in ... amphibians can acquire behavioral or immunological resistance to ... population declines. , "Acquired resistance is important ...
(Date:7/9/2014)... Researchers from The Cancer Genome Atlas (TCGA) Research ... cancer-causing pathway in lung adenocarcinoma, the most common ... changes may expand the number of possible therapeutic ... greater number of patients with treatable mutations because ... already exist. , TCGA is jointly funded and ...
(Date:7/9/2014)... new study shows that some shark species may be able ... may come with rising temperatures. , The Arctic today is ... it wasn,t always like that. Roughly 53 to 38 million ... the Arctic was more similar to a huge temperate forest ... including ancestors of tapirs, hippo-like creatures, crocodiles and giant tortoises. ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... replace lost teeth with titanium dental implants could be improved. ... at micro level but also at nano level, researchers at ... method that could shorten the healing time for patients. , ... conductivity of the implant allows us to affect the body,s ...
... new type of cell in the immune system. ... belongs to a family of T-cells that play a critical ... could ultimately lead to the development of novel drugs that ... It is also potentially significant for many other ...
... 2011 Numera, a leading provider of innovative ... entered into a strategic partnership with HealthTrio LLC. ... integrate objective, biometric information from dozens of consumer-preferred ... Health Record (PHR). This new functionality will be ...
Cached Biology News:Healing times for dental implants could be cut 2New cell type offers immunology hope 2Numera and HealthTrio LLC Form Partnership to Provide Objective Health Information for Millions of Consumers 2Numera and HealthTrio LLC Form Partnership to Provide Objective Health Information for Millions of Consumers 3